Drug Trial Radar · NCT06012734
LB-100 (PP2A Inhibitor) and Atezolizumab (PD-L1 Inhibitor) in Metastatic Colorectal Cancer Patients
Last checked: Nov 19, 2026Latest source record: Jun 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
37
Planned (sponsor's estimate)
Start
Jun 18, 2024
Primary completion
Jul 2028
Study completion Jul 2028
Sponsor
- Lead sponsor
- The Netherlands Cancer InstituteAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Aug 25, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This Phase Ib trial studies the side effects and best dose of LB-100 when given with atezolizumab for the treatment of patients with metastatic microsatellite stable colorectal cancer. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of the tumor to grow and spread. LB-100 has been shown to make anticancer drugs work better at killing cancer. LB-100 blocks a protein on the surface of cells called PP2A. Blocking this protein increases the stress signals for the tumor cells that express PP2A. Giving atezolizumab in combination with LB-100 may work better to treat metastatic colorectal cancer patients as the cancer cells that experience increased stress signals are more susceptible for the immunotherapy.
Conditions
- Metastatic Microsatellite-stable Colorectal Cancer
Interventions
LB-100Drug
IV on day 1 and day 3
AtezolizumabDrug
IV on day 1
Primary outcomes
What the sponsor says the trial is designed to measure.
- The RP2D of LB-100 when given in combination with standard doses of atezolizumabTime frame: up to 2 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Antoni van Leeuwenhoek
Amsterdam, North Holland, Netherlands · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.